Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 30

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 30
---
.

6

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Three Months Ended March 31,(in millions)20252024Net income (loss)$672 $493 Adjustments to reconcile net income (loss) to cash provided by (used for) operating activitiesDepreciation and amortization325 304 Deferred and prepaid income taxes41 31 Stock-based compensation expense74 63 Net loss (gain) on investments and notes receivable28 2 Contingent consideration net expense (benefit)5 17 Inventory step-up amortization81 — Other, net(7)(4)Increase (decrease) in operating assets and liabilities, excluding purchase accounting:Trade accounts receivable(107)(114)Inventories(109)(124)Other assets(77)(55)Accounts payable, accrued expenses and other liabilities(385)(450)Cash provided by (used for) operating activities541 164 Investing activities:  Purchases of property, plant and equipment and internal use software(187)(179)Payments for acquisitions of businesses, net of cash acquired(239)(47)Payments for investments and acquisitions of certain technologies(77)(66)Other, net3 7 Cash provided by (used for) investing activities(500)(285)Financing activities:  Payment of contingent consideration previously established in purchase accounting— (34)Payments for royalty rights(10)(15)Payments for finance leases(36)(25)Payments on short-term borrowings(1,083)(504)Net increase (decrease) in commercial paper(192)— Proceeds from long-term borrowings, net of debt issuance costs1,558 2,145 Cash used to net share settle employee equity awards(118)(78)Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans115 80 Cash provided by (used for) financing activities233 1,569 Effect of foreign exchange rates on cash39 (7)Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents314 1,441 Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period606 1,055 Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$919 $2,496 

Refer to notes to the unaudited consolidated financial statements